At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
Tivantinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Placebo, and 1 other intervention for Hormone-Resistant Prostate Cancer and 3 related conditions. Completed, enrolled 78 participants across 20 sites.
Detailed Summary
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJan 2012
Primary CompletionAug 2015
TodayJul 2026
First PostedJan 27, 2012
Enrollment StartJan 11, 2012
Primary CompletionAug 18, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.4 years ago
Interventions
Laboratory Biomarker Analysisother
Optional correlative studies
Placeboother
Given PO
Tivantinibdrug
Given PO